BMJ Case Reports · 2018 · 49 citations · 19 references
Life SciencesImmunologyPharmacologyAutoimmunityImmunoregulationImmunotherapyAutoimmune Disease ImmunotherapyAutoimmune DiseasesImmunomodulatory Drug TherapyImmunomodulatory DrugsImmunosuppressionMast Cell ActivationAntibody Production ImpairmentAutoimmune Neuromuscular Junction DisordersCell ActivationLymphocyte PhysiologyMast Cell Activation DisordersNaltrexone TreatmentOpioid Antagonist TherapyPeripheral Regulatory T Cells
A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role.
19
Autoimmune Basis for Postural Tachycardia Syndrome
Hongliang Li, Xichun Yu, Campbell Liles et al. · Journal of the American Heart Association · 2014 · 248 citations · Full text
Hyperadrenergic Postural Tachycardia Syndrome in Mast Cell Activation Disorders
Cyndya A. Shibao, Carmen Arzubiaga, L. Jackson Roberts et al. · Hypertension · 2005 · 221 citations
Characterization of Mast Cell Activation Syndrome
Lawrence B. Afrin, Sally Self, Jeremiah Menk et al. · The American Journal of the Medical Sciences · 2016 · 96 citations